Tributary Capital Management’s Genomic Health, Inc. GHDX Stock Holding History

Tributary Capital Management’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-318,887	Closed	-$10.9M	–	243
2017 Q4	$10.9M	Sell	318,887 -9,506	-3%	-$303K	0.95%	55
2017 Q3	$10.5M	Sell	328,393 -1,192	-0.4%	-$37.6K	0.91%	58
2017 Q2	$10.7M	Buy	329,585 +34,623	+12%	+$1.1M	0.95%	52
2017 Q1	$9.29M	Buy	294,962 +57,591	+24%	+$1.7M	0.91%	53
2016 Q4	$6.98M	Buy	237,371 +16,017	+7%	+$488K	0.82%	52
2016 Q3	$6.4M	Buy	221,354 +15,063	+7%	+$420K	0.83%	52
2016 Q2	$5.34M	Buy	206,291 +21,705	+12%	+$576K	0.78%	52
2016 Q1	$4.57M	Buy	184,586 +5,817	+3%	+$160K	0.72%	57
2015 Q4	$6.29M	Sell	178,769 -60,028	-25%	-$1.61M	1.04%	30
2015 Q3	$5.05M	Buy	238,797 +37,307	+19%	+$961K	0.84%	43
2015 Q2	$5.6M	Buy	201,490 +39,694	+25%	+$1.12M	0.87%	40
2015 Q1	$4.94M	Buy	161,796 +10,900	+7%	+$347K	0.77%	54
2014 Q4	$4.82M	Buy	150,896 +39,652	+36%	+$1.29M	0.82%	46
2014 Q3	$3.15M	Buy	111,244 +11,575	+12%	+$323K	0.66%	73
2014 Q2	$2.73M	Buy	+99,669	New	+$2.65M	0.55%	103

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Tributary Capital Management's GHDX Position: Q1 2018 in Review

Tributary Capital Management sold out of Genomic Health, Inc. (GHDX) in Q1 2018, closing a stake of 318,887 shares — an estimated $10.9M sold.

Tributary Capital Management first reported a position in GHDX in Q2 2014 and held it in 15 quarters. The position peaked at $10.9M in Q4 2017. 134 funds tracked by Wall St. Rank hold GHDX as of Q1 2018.

Tributary Capital Management reported no remaining Genomic Health, Inc. position as of Q1 2018 after selling out during the quarter.
Tributary Capital Management sold 318,887 Genomic Health, Inc. shares in Q1 2018, an estimated $10.9M.
Tributary Capital Management first reported a position in Genomic Health, Inc. in Q2 2014 and held it in 15 quarters.
Tributary Capital Management's Genomic Health, Inc. position peaked at $10.9M in Q4 2017.
134 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q1 2018.

Based on Tributary Capital Management's 13F filing for Q1 2018, filed 19 Apr 2018.